Nymox Pharm Corp (NYMX) 3.62 $NYMX
Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show
GlobeNewswire - Mon Aug 29, 9:30AM CDT
1. Dramatic Decrease in Prostate Cancer and
NYMX: 3.62 (+0.08)
Why Nymox Pharma (NYMX) Closed the Day Up 83%
Madeleine Johnson - Zacks Investment Research - Wed Aug 24, 5:02PM CDT
On Wednesday, shares of drug researcher and developer Nymox Pharmaceuticals Corp. (NYMX) skyrocketed, closing the day up over 83% on news that the company???s long-term trial for an enlarged prostate (BPH) and prostate cancer drug was successful.
NYMX: 3.62 (+0.08)
Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery
GlobeNewswire - Wed Aug 24, 11:18AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer. The aim of the study was to determine the clinical benefit fexapotide can provide to men who initially were double blind randomized to and received placebo, remained blinded as to their placebo treatment, and who subsequently required additional medical and/or surgical treatment. In the new study long-term outcomes were determined in 391 patients who were given double blind placebo injections, which were followed by crossover to other treatments at the patients' discretion. The numbers of blinded placebo patients who subsequently received surgical treatment during the next 2-3 years for their BPH symptoms were then prospectively analyzed. Results have now shown that there was 82-95% reduction in the number of these patients who required surgery after they received crossover fexapotide in the trial, as compared to patients who did not receive fexapotide but instead received crossover conventional approved BPH treatments (p<.0001).
NYMX: 3.62 (+0.08)
Nymox Announces Prostate Drug Progress
GlobeNewswire - Thu Aug 11, 9:28AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce major progress in the evidence for the safety and efficacy of fexapotide, the Company's Phase 3 drug in the final stages of development for prostate enlargement (BPH) and for low grade prostate cancer. Fexapotide has completed 2 long-term large Phase 3 BPH studiesâ?? in the U.S. No other new prostate drug injectable currently in development has previously succeeded in enrolling and completing a fully U.S. study close to the size of either of Nymox's 2 long-term studies. In addition, no other injectable prostate enlargement drug has previously been shown to have the excellent long-term safety and efficacy profile of fexapotide.
NYMX: 3.62 (+0.08)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nymox Pharmaceutical Corporation (NYMX)
ACCESSWIRE - Thu Aug 11, 9:21AM CDT
NEW YORK, NY / ACCESSWIRE / August 11, 2016 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
(NASDAQ: NYMX). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484.
NYMX: 3.62 (+0.08)
Nymox Pharmaceutical Corporation Investigated For Securities Fraud By Block & Leviton After Report Reveals Pervasive Misconduct By The Company
PR Newswire - Thu Aug 11, 4:00AM CDT
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Nymox Pharmaceutical Corporation ("Nymox" or the "Company" (NASDAQ: NYMX) and certain of its officers and directors violated federal securities laws.
NYMX: 3.62 (+0.08)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Nymox Pharmaceutical Corporation and Advises Investors with Losses to Contact the Firm
BusinessWire - Wed Aug 10, 9:25PM CDT
Lundin Law PC (http://lundinlawpc.com/) announces that it is investigating claims against Nymox Pharmaceutical Corporation ("Nymox" or the "Company" (Nasdaq: NYMX) concerning possible violations of federal securities laws.
NYMX: 3.62 (+0.08)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nymox Pharmaceutical Corporation - NYMX
PR Newswire - Wed Aug 10, 3:53PM CDT
Pomerantz LLP is investigating claims on behalf of investors of Nymox Pharmaceutical Corporation ("Nymox" or the "Company" (NASDAQ: NYMX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.
NYMX: 3.62 (+0.08)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Nymox Pharmaceutical Corporation
BusinessWire - Wed Aug 10, 11:36AM CDT
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Nymox Pharmaceutical Corporation (NASDAQ: NYMX) resulting from allegations that Nymox may have issued materially misleading business information to the investing public.
NYMX: 3.62 (+0.08)
Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:51AM CDT
Nymox (NYMX) announced positive results from the seven-year, prospective, placebo-controlled, double-blind study on fexapotide (NX-1207).
ANIP: 59.86 (-1.56), PFE: 34.77 (+0.09), RTRX: 16.10 (-0.25), NYMX: 3.62 (+0.08)
Nymox reports 1Q loss
Automated Insights - Mon May 16, 5:11PM CDT
MONTREAL (AP) _ Nymox Pharmaceutical Corp. (NYMX) on Monday reported a first-quarter loss of $3.3 million, after reporting a profit in the same period a year earlier.
NYMX: 3.62 (+0.08)
Nymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study
GlobeNewswire - Tue Feb 09, 10:07AM CST
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) today announced results from the completion of the Company's U.S. 40 month (18 month outcomes) localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207). The study successfully met its pre-determined endpoints. Cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups.
NYMX: 3.62 (+0.08)
Nymox raises another USD2.1m from equity financing
M2 - Fri Feb 05, 5:02AM CST
Biopharmaceutical company Nymox Pharmaceutical (NasdaqCM:NYMX) reported on Thursday the completion of USD2.1m private placement equity investment at USD2.00 per share with no warrants.
NYMX: 3.62 (+0.08)
Escherichia Coli Infections - Pipeline Review, H2 2015
M2 - Mon Feb 01, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/96468r/escherichia_coli) has announced the addition of the "Escherichia coli Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Escherichia Coli Infections Overview - Therapeutics Development - Pipeline Products for Escherichia Coli Infections - Overview - Pipeline Products for Escherichia Coli Infections - Comparative Analysis - Escherichia Coli Infections - Therapeutics under Development by Companies - Escherichia Coli Infections - Therapeutics under Investigation by Universities/Institutes - Escherichia Coli Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Escherichia Coli Infections - Products under Development by Companies - Escherichia Coli Infections - Products under Investigation by Universities/Institutes - Escherichia Coli Infections - Companies Involved in Therapeutics Development - Adenium Biotech ApS - Arsanis Biosciences GmbH - AstraZeneca Plc - AvidBiotics Corp. - Bioorganic Research and Services S.A. - Cellceutix Corporation - Chiesi Farmaceutici SpA - Debiopharm International S.A. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - GangaGen Inc. - GlaxoSmithKline Plc - Immuron Limited - Melinta Therapeutics, Inc - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - Mucosis B.V. - Navigen Pharmaceuticals, Inc. - Nosopharm SAS - Novabiotics Limited - Nymox Pharmaceutical Corporation - Pherecydes Pharma SA - Phico Therapeutics Limited - Procarta Biosystems Ltd - Sanofi Pasteur SA - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Soligenix, Inc. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - Trana Discovery, Inc. - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/96...ichia_coli
TTPH: 3.72 (-0.06), EBS: 26.90 (+0.49), AZN: 33.31 (+0.71), NYMX: 3.62 (+0.08), GSK: 44.26 (+1.28)
Nymox Files Current Financial Statements
GlobeNewswire - Thu Dec 31, 3:45PM CST
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that today the Company has filed its third quarter 2015 and restated second quarter 2015 financial statements. The financial results are available at - http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany. The restatement of Q2 2015 was required in order to correct a material accounting error in stock option compensation expense.
NYMX: 3.62 (+0.08)
Nymox Provides Update From Shareholders Annual General Meeting December 16
GlobeNewswire - Thu Dec 17, 8:00AM CST
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report an update on the Corporation's business as of December 16, 2015. At the Company's AGM in Nassau, the following highlights were presented:
NYMX: 3.62 (+0.08)
World Benign Prostatic Hyperplasia Therapeutics Pipeline Review 2015 - 25 Companies & 36 Drug Profiles
M2 - Mon Dec 14, 8:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/46clxb/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AmVac AG - AndroScience Corporation - Aphios Corporation - Ausio Pharmaceuticals, LLC - BCWorld Pharm Co. Ltd. - Biolab Sanus Farmaceutica Ltda. - Chong Kun Dang Pharmaceutical Corp. - Dongkook Pharmaceutical Co., Ltd. - Euroscreen S.A. - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Jeil Pharmaceutical Co., Ltd. - KAEL-GemVax Co., Ltd. - Kaken Pharmaceutical Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - Monosol Rx, LLC - Nymox Pharmaceutical Corporation - Ono Pharmaceutical Co., Ltd. - Quest PharmaTech Inc. - SK Chemicals Co., Ltd. - SOM Innovation Biotech SL - Sophiris Bio, Inc. - Yungjin Pharm. Co., Ltd. Drug Profiles - (dutasteride tadalafil) - (solifenacin succinate tamsulosin hydrochloride) - (tamsulosin hydrochloride dutasteride) - ADX-68692 - AMV-110 - ASC-JM.X2 - AUS-131 - BCWPE-004 - BL-214 - CKD-902 - ESN-364 - fexapotide triflutate - HCP-1303 - HIP-1402 - INT-0031 - L-1AD3 - MCS-2 - Micselon - NCE-403 - ONO-8430506 - S-40542 - SL-052 - Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - SOM-2391 - SOM-2393 - Sperol - Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - tadalafil - talaporfin sodium - tamsulosin hydrochloride CR - tamsulosin hydrochloride DR - tertomotide - topsalysin - udenafil - YBH-1603 For more information visit http://www.researchandmarkets.com/research/46..._prostatic
SPHS: 3.11 (+0.17), NYMX: 3.62 (+0.08)
Analyst Insights behind Price Movement - Research on Vascular Biogenics, Hutchinson Technology, Tonix Pharmaceuticals and Nymox Pharmaceutical
ACCESSWIRE - Mon Nov 23, 7:40AM CST
NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Vascular Biogenics Ltd (NASDAQ: VBLT), Hutchinson Technology Inc (NASDAQ: HTCH), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and Nymox Pharmaceutical Corp (NASDAQ: NYMX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
HTCH: 1.49 (unch), TNXP: 2.18 (-0.18), NYMX: 3.62 (+0.08), VBLT: 4.09 (+0.03)
Urinary Tract Infections - Pipeline Review, H2 2015
M2 - Fri Nov 06, 9:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/fx43r6/urinary_tract) has announced the addition of the "Urinary Tract Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Achaogen Inc. - Adenium Biotech ApS - AstraZeneca Plc - ConjuGon, Inc. - Da Volterra - DexTech Medical AB - Enteris BioPharma, Inc. - GlaxoSmithKline Plc - Melinta Therapeutics, Inc - Merck & Co., Inc. - MerLion Pharmaceuticals Pte Ltd - Nabriva Therapeutics AG - Nippon Shinyaku Co., Ltd. - NovaBay Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - Paratek Pharmaceuticals, Inc. - Pivot Pharmaceuticals Inc - Sequoia Sciences, Inc. - Shionogi & Co., Ltd. - Syntiron LLC - The Medicines Company - Zensun (Shanghai) Sci & Tech Co., Ltd. For more information visit http://www.researchandmarkets.com/research/fx...nary_tract
MRK: 62.98 (+0.08), AZN: 33.31 (+0.71), AKAO: 4.25 (+0.26), NYMX: 3.62 (+0.08), PRTK: 13.61 (+0.25), GSK: 44.26 (+1.28), NBRV: 7.63 (-0.14)
Nymox's New Phase 3 Long-Term U.S. Results For Prostate Enlargement Drug Fexapotide Show
GlobeNewswire - Mon Aug 29, 9:30AM CDT
1. Dramatic Decrease in Prostate Cancer and
NYMX: 3.62 (+0.08)
Why Nymox Pharma (NYMX) Closed the Day Up 83%
Madeleine Johnson - Zacks Investment Research - Wed Aug 24, 5:02PM CDT
On Wednesday, shares of drug researcher and developer Nymox Pharmaceuticals Corp. (NYMX) skyrocketed, closing the day up over 83% on news that the company???s long-term trial for an enlarged prostate (BPH) and prostate cancer drug was successful.
NYMX: 3.62 (+0.08)
Nymox Reports Successful New Long-Term Fexapotide Placebo Crossover Study Results: Major Reduction in Incidence of Surgery
GlobeNewswire - Wed Aug 24, 11:18AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce successful new study results from the long-term blinded placebo crossover group from the U.S. Phase 3 trials for fexapotide, the Company's lead compound in late stage development for enlarged prostate (BPH) and for localized prostate cancer. The aim of the study was to determine the clinical benefit fexapotide can provide to men who initially were double blind randomized to and received placebo, remained blinded as to their placebo treatment, and who subsequently required additional medical and/or surgical treatment. In the new study long-term outcomes were determined in 391 patients who were given double blind placebo injections, which were followed by crossover to other treatments at the patients' discretion. The numbers of blinded placebo patients who subsequently received surgical treatment during the next 2-3 years for their BPH symptoms were then prospectively analyzed. Results have now shown that there was 82-95% reduction in the number of these patients who required surgery after they received crossover fexapotide in the trial, as compared to patients who did not receive fexapotide but instead received crossover conventional approved BPH treatments (p<.0001).
NYMX: 3.62 (+0.08)
Nymox Announces Prostate Drug Progress
GlobeNewswire - Thu Aug 11, 9:28AM CDT
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce major progress in the evidence for the safety and efficacy of fexapotide, the Company's Phase 3 drug in the final stages of development for prostate enlargement (BPH) and for low grade prostate cancer. Fexapotide has completed 2 long-term large Phase 3 BPH studiesâ?? in the U.S. No other new prostate drug injectable currently in development has previously succeeded in enrolling and completing a fully U.S. study close to the size of either of Nymox's 2 long-term studies. In addition, no other injectable prostate enlargement drug has previously been shown to have the excellent long-term safety and efficacy profile of fexapotide.
NYMX: 3.62 (+0.08)
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Nymox Pharmaceutical Corporation (NYMX)
ACCESSWIRE - Thu Aug 11, 9:21AM CDT
NEW YORK, NY / ACCESSWIRE / August 11, 2016 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
(NASDAQ: NYMX). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484. NYMX: 3.62 (+0.08)
Nymox Pharmaceutical Corporation Investigated For Securities Fraud By Block & Leviton After Report Reveals Pervasive Misconduct By The Company
PR Newswire - Thu Aug 11, 4:00AM CDT
Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
(NASDAQ: NYMX) and certain of its officers and directors violated federal securities laws. NYMX: 3.62 (+0.08)
IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces an Investigation of Nymox Pharmaceutical Corporation and Advises Investors with Losses to Contact the Firm
BusinessWire - Wed Aug 10, 9:25PM CDT
Lundin Law PC (http://lundinlawpc.com/) announces that it is investigating claims against Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
(Nasdaq: NYMX) concerning possible violations of federal securities laws. NYMX: 3.62 (+0.08)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nymox Pharmaceutical Corporation - NYMX
PR Newswire - Wed Aug 10, 3:53PM CDT
Pomerantz LLP is investigating claims on behalf of investors of Nymox Pharmaceutical Corporation ("Nymox" or the "Company"
(NASDAQ: NYMX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980. NYMX: 3.62 (+0.08)
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Nymox Pharmaceutical Corporation
BusinessWire - Wed Aug 10, 11:36AM CDT
Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Nymox Pharmaceutical Corporation (NASDAQ: NYMX) resulting from allegations that Nymox may have issued materially misleading business information to the investing public.
NYMX: 3.62 (+0.08)
Nymox (NYMX) Stock Up on Positive 7-Year Fexapotide Data
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:51AM CDT
Nymox (NYMX) announced positive results from the seven-year, prospective, placebo-controlled, double-blind study on fexapotide (NX-1207).
ANIP: 59.86 (-1.56), PFE: 34.77 (+0.09), RTRX: 16.10 (-0.25), NYMX: 3.62 (+0.08)
Nymox reports 1Q loss
Automated Insights - Mon May 16, 5:11PM CDT
MONTREAL (AP) _ Nymox Pharmaceutical Corp. (NYMX) on Monday reported a first-quarter loss of $3.3 million, after reporting a profit in the same period a year earlier.
NYMX: 3.62 (+0.08)
Nymox Announces Prostate Cancer Clinical Trial Results From Completed 18 Month Endpoint Study
GlobeNewswire - Tue Feb 09, 10:07AM CST
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) today announced results from the completion of the Company's U.S. 40 month (18 month outcomes) localized prostate cancer Phase 2 NX03-0040 clinical trial of fexapotide triflutate (NX-1207). The study successfully met its pre-determined endpoints. Cancer progression clinical outcomes were significantly improved in the fexapotide treated patient groups.
NYMX: 3.62 (+0.08)
Nymox raises another USD2.1m from equity financing
M2 - Fri Feb 05, 5:02AM CST
Biopharmaceutical company Nymox Pharmaceutical (NasdaqCM:NYMX) reported on Thursday the completion of USD2.1m private placement equity investment at USD2.00 per share with no warrants.
NYMX: 3.62 (+0.08)
Escherichia Coli Infections - Pipeline Review, H2 2015
M2 - Mon Feb 01, 10:20AM CST
Research and Markets (http://www.researchandmarkets.com/research/96468r/escherichia_coli) has announced the addition of the "Escherichia coli Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Escherichia Coli Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Escherichia Coli Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Escherichia Coli Infections Overview - Therapeutics Development - Pipeline Products for Escherichia Coli Infections - Overview - Pipeline Products for Escherichia Coli Infections - Comparative Analysis - Escherichia Coli Infections - Therapeutics under Development by Companies - Escherichia Coli Infections - Therapeutics under Investigation by Universities/Institutes - Escherichia Coli Infections - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Escherichia Coli Infections - Products under Development by Companies - Escherichia Coli Infections - Products under Investigation by Universities/Institutes - Escherichia Coli Infections - Companies Involved in Therapeutics Development - Adenium Biotech ApS - Arsanis Biosciences GmbH - AstraZeneca Plc - AvidBiotics Corp. - Bioorganic Research and Services S.A. - Cellceutix Corporation - Chiesi Farmaceutici SpA - Debiopharm International S.A. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - GangaGen Inc. - GlaxoSmithKline Plc - Immuron Limited - Melinta Therapeutics, Inc - Microbiotix, Inc. - MicuRx Pharmaceuticals, Inc. - Mucosis B.V. - Navigen Pharmaceuticals, Inc. - Nosopharm SAS - Novabiotics Limited - Nymox Pharmaceutical Corporation - Pherecydes Pharma SA - Phico Therapeutics Limited - Procarta Biosystems Ltd - Sanofi Pasteur SA - Sealife PHARMA GMBH - Sequoia Sciences, Inc. - Soligenix, Inc. - Syntiron LLC - Tetraphase Pharmaceuticals Inc. - Trana Discovery, Inc. - Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/96...ichia_coli
TTPH: 3.72 (-0.06), EBS: 26.90 (+0.49), AZN: 33.31 (+0.71), NYMX: 3.62 (+0.08), GSK: 44.26 (+1.28)
Nymox Files Current Financial Statements
GlobeNewswire - Thu Dec 31, 3:45PM CST
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to announce that today the Company has filed its third quarter 2015 and restated second quarter 2015 financial statements. The financial results are available at - http://www.sec.gov/cgi-bin/browse-edgar?compa...getcompany. The restatement of Q2 2015 was required in order to correct a material accounting error in stock option compensation expense.
NYMX: 3.62 (+0.08)
Nymox Provides Update From Shareholders Annual General Meeting December 16
GlobeNewswire - Thu Dec 17, 8:00AM CST
Nymox Pharmaceutical Corporation (NASDAQ:NYMX) is pleased to report an update on the Corporation's business as of December 16, 2015. At the Company's AGM in Nassau, the following highlights were presented:
NYMX: 3.62 (+0.08)
World Benign Prostatic Hyperplasia Therapeutics Pipeline Review 2015 - 25 Companies & 36 Drug Profiles
M2 - Mon Dec 14, 8:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/46clxb/benign_prostatic) has announced the addition of the "Benign Prostatic Hyperplasia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Benign Prostatic Hyperplasia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Benign Prostatic Hyperplasia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Addex Therapeutics Ltd - AmVac AG - AndroScience Corporation - Aphios Corporation - Ausio Pharmaceuticals, LLC - BCWorld Pharm Co. Ltd. - Biolab Sanus Farmaceutica Ltda. - Chong Kun Dang Pharmaceutical Corp. - Dongkook Pharmaceutical Co., Ltd. - Euroscreen S.A. - Hanmi Pharmaceuticals, Co. Ltd. - IntelGenx Corp. - Jeil Pharmaceutical Co., Ltd. - KAEL-GemVax Co., Ltd. - Kaken Pharmaceutical Co., Ltd. - Meiji Seika Pharma Co., Ltd. - Mezzion Pharma Co. Ltd. - Monosol Rx, LLC - Nymox Pharmaceutical Corporation - Ono Pharmaceutical Co., Ltd. - Quest PharmaTech Inc. - SK Chemicals Co., Ltd. - SOM Innovation Biotech SL - Sophiris Bio, Inc. - Yungjin Pharm. Co., Ltd. Drug Profiles - (dutasteride tadalafil) - (solifenacin succinate tamsulosin hydrochloride) - (tamsulosin hydrochloride dutasteride) - ADX-68692 - AMV-110 - ASC-JM.X2 - AUS-131 - BCWPE-004 - BL-214 - CKD-902 - ESN-364 - fexapotide triflutate - HCP-1303 - HIP-1402 - INT-0031 - L-1AD3 - MCS-2 - Micselon - NCE-403 - ONO-8430506 - S-40542 - SL-052 - Small Molecules to Inhibit Steroidal 5-Alpha Reductase for Benign Prostatic Hyperplasia - SOM-2391 - SOM-2393 - Sperol - Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - tadalafil - talaporfin sodium - tamsulosin hydrochloride CR - tamsulosin hydrochloride DR - tertomotide - topsalysin - udenafil - YBH-1603 For more information visit http://www.researchandmarkets.com/research/46..._prostatic
SPHS: 3.11 (+0.17), NYMX: 3.62 (+0.08)
Analyst Insights behind Price Movement - Research on Vascular Biogenics, Hutchinson Technology, Tonix Pharmaceuticals and Nymox Pharmaceutical
ACCESSWIRE - Mon Nov 23, 7:40AM CST
NEW YORK, NY / ACCESSWIRE / November 23, 2015 / Moments ago, Trader's Choice released new research updates concerning several important developing situations including the following equities: Vascular Biogenics Ltd (NASDAQ: VBLT), Hutchinson Technology Inc (NASDAQ: HTCH), Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) and Nymox Pharmaceutical Corp (NASDAQ: NYMX). Trader's Choice has perfected the profitable art of picking stocks, cutting through the noise to deliver the top trade, every year. The full Research Packages are being made available to the public on a complimentary basis.
HTCH: 1.49 (unch), TNXP: 2.18 (-0.18), NYMX: 3.62 (+0.08), VBLT: 4.09 (+0.03)
Urinary Tract Infections - Pipeline Review, H2 2015
M2 - Fri Nov 06, 9:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/fx43r6/urinary_tract) has announced the addition of the "Urinary Tract Infections - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Mentioned - Achaogen Inc. - Adenium Biotech ApS - AstraZeneca Plc - ConjuGon, Inc. - Da Volterra - DexTech Medical AB - Enteris BioPharma, Inc. - GlaxoSmithKline Plc - Melinta Therapeutics, Inc - Merck & Co., Inc. - MerLion Pharmaceuticals Pte Ltd - Nabriva Therapeutics AG - Nippon Shinyaku Co., Ltd. - NovaBay Pharmaceuticals, Inc. - Nymox Pharmaceutical Corporation - Paratek Pharmaceuticals, Inc. - Pivot Pharmaceuticals Inc - Sequoia Sciences, Inc. - Shionogi & Co., Ltd. - Syntiron LLC - The Medicines Company - Zensun (Shanghai) Sci & Tech Co., Ltd. For more information visit http://www.researchandmarkets.com/research/fx...nary_tract
MRK: 62.98 (+0.08), AZN: 33.31 (+0.71), AKAO: 4.25 (+0.26), NYMX: 3.62 (+0.08), PRTK: 13.61 (+0.25), GSK: 44.26 (+1.28), NBRV: 7.63 (-0.14)
